Combining Gene Editing and iPSC Technologies
for Preclinical Discovery and Translational Research
Watch our webinar on-demand to hear Ruby Chen-Tsai, Ph.D., CSO of Applied StemCell, discuss how her team is using genome engineering and iPSC technologies to advance disease modeling, lead compound discovery, and bioproduction.
You will learn about:
- Using genome engineering technologies for the generation of preclinical research models
- How genome editing technologies can be applied to the development of cell and gene therapies
- Application of gene editing to bioproduction
- CRISPR-mediated gene editing for the development of nucleic acid reference standards
About Our Speaker
Ruby Yanru Chen-Tsai, Ph.D. has worked on the development and modification of stem cells and pre-clinical models for over 25 years. Prior to Applied StemCell, Dr. Chen-Tsai was at Stanford University, where she served as Director of the Transgenic Research Center and Associate Director of the Stanford Cancer Institute. Dr. Chen-Tsai is a co-inventor of the TARGATT™ integrase technology and the “DICE” platform for site-specific gene insertion. Her current research focuses on pre-clinical model development, as well as gene- and stem cell-based therapies using genome editing technologies including CRISPR/Cas9 and TARGATT™ integrase.